Biotech Top Losers: Rexahn Pharmaceuticals (NYSEMKT:RNN), Aegerion Pharmaceuticals (NASDAQ:AEGR), Enzymotec Ltd (NASDAQ:ENZY), Can Fite Biopharma (NYSEMKT:CANF)

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on Mar. 3 announced the appointment of Mark P. Carthy to the company’s Board of Directors. Mr. Carthy is the Managing Partner of Orion Equity Partners, LLC, a healthcare venture capital management and advisory firm co-founded by Mr. Carthy in 2008. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock performance was -5.68% in last session and finished the day at $1.25. Traded volume was 8,481,422 million shares in the last session and the average volume of the stock remained 11.17 million shares. The beta of the stock remained 1.21. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) insider ownership is 4.40%.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was a big mover last session, as its shares rose nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the healthcare company since Feb 24, as the stock is now down nearly 19%. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) dropped -5.53 percent to $52.46 yesterday on volume of 877,728.00 million shares. The intra-day range of the stock was $ 51.40 to $55.29. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has a market capitalization of $1.54 million.

Enzymotec, Ltd (NASDAQ:ENZY) a biotech company hailing from Migdal Ha’emek, jacked up its Nasdaq offering to 4.7 million shares, priced at $28 a pop. All the shares are being sold by company shareholders, meaning Enzymotec itself, which makes lipid-based products, won’t be getting a sou. Enzymotec Ltd (NASDAQ:ENZY)’s stock on Mar 10, 2014 reported a decrease of -5.94% to the closing price of $25.96. Its fifty two weeks range is $14.25 -$35.12. The total market capitalization recorded $564.90 million. The overall volume in the last trading session was 154,188 million shares. In its share capital, Enzymotec Ltd (NASDAQ:ENZY) has 21.55 million outstanding shares.

Can-Fite BioPharma Ltd. (ADR) (NYSEMKT:CANF) announced that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million. On Monday, shares of Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) dropped -5.47% to close the day at $5.53. Company’s monthly performance is recorded as 0.18%. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) quarterly revenue growth is -14.92%.